Nikita V. Chumovatov

Nikita V. Chumovatov

Auto-generated profile, based on publicly available information

Nikita V. Chumovatov

Central Tuberculosis Research Institute

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
NCN. V. Chumovatov
N. V. Chumovatov
VEV. E. Eremeev
V. E. Eremeev
AEA. E. Ergeshov
A. E. Ergeshov
The problem of smoking, as well as incidence of tuberculosis, has existed for a long time. The latest WHO data indicate that 1.3 million people die from tuberculosis, and another 7 millions die from smoking every year. Tobacco smoke contains many harmful chemicals, including carbon monoxide, nicotine, nitrogen oxides, and cadmium. A number of studies indicate a high prevalence of smoking among patients with tuberculosis. In most cases, infection with Mycobacterium tuberculosis does not lead to active disease, due to the development of a balanced, homeostatic immune response. The key protective components are inflammatory responses aimed at inhibition of the pathogen growth, its sequestration and final elimination. At the same time, excessive or inadequate immune response may lead to granuloma destruction, tissue damage and, as a result, prolonged duration of treatment due to decreased respiratory function of the lungs. Along with pro-inflammatory mediators, anti-inflammatory mediators are synthesized in the host organism, which can positively or negatively affect the course of disease, depending on the place and time of their production. The balance between pro-and anti-inflammatory mediators in terms of time and expression level plays a crucial role in determining the outcome of infection. In our review, we consider the impact of tobacco smoke on various components of the human immune system, as well as upon the course and outcome of tuberculosis and other lung diseases. In addition, we would like to draw the reader’s attention to the need of adjusting pathogenetic therapy of bronchopulmonary diseases, taking into account the patient’s smoking habits. Tobacco smoking is one of the main causes of the severe course of many infectious and non-infectious diseases of the bronchopulmonary system. The decay products of cigarette smoke disrupt the functioning of the ciliated epithelium of respiratory tract, the production of the mucous component in the bronchi, and reduce the effectiveness of the surfactant system. These negative events interfere with protective mechanisms of the human respiratory system. It is worth of note that tobacco smoke also exerts a systemic effect on the immune system. Data are accumulating on the association between the terms of exposure to tobacco smoke, and a range of adverse tunerculosis manifestations, such as extent of infection, severity of course, reactivation, treatment outcome, and mortality. At the same time, epidemiological studies are able to reveal the associations, but they do not allow us to determine exact causal relationships.

1 January 2022 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
NCN.V. Chumovatov
N.V. Chumovatov
NAN.S. Antonov
N.S. Antonov
GSG.M. Sakharova
G.M. Sakharova
VRV.V. Romanov
V.V. Romanov
AEA.E. Ergeshov
A.E. Ergeshov
Во всем мире табакокурение и заболевания туберкулезом легких представляют собой проблему здравоохранения на протяжении длительного времени. За последние годы наблюдался значительный рост лекарственной устойчивости микобактерии туберкулеза, что приводит к снижению эффективности проводимой терапии. Также неуклонно растет и распространенность курения среди пациентов с туберкулезом легких. В связи с этим является актуальным проанализировать связь табакокурения и клинического течения туберкулезной инфекции. ЦЕЛЬ ИССЛЕДОВАНИЯ Провести количественную оценку ассоциации табакокурения с основными клиническими формами и тяжестью течения туберкулеза легких. МАТЕРИАЛ И МЕТОДЫ Проведен анализ медицинской документации пациентов в отделе фтизиатрии ФГБНУ ЦНИИТ за период с 2018 по 2020 г. В группу исследования были включены 60 пациентов в возрасте 18 лет и старше с подтвержденным туберкулезом легких, из которых 31 являлся курильщиком и 29 никогда не курили. РЕЗУЛЬТАТЫ Табакокурение ассоциировано с более тяжелым течением туберкулеза легких, требующим длительной интенсивной терапии. Статистически значимо табакокурение связано с фиброзно-кавернозной и другими распространенными формами туберкулеза легких, наличием бактериовыделения, которые встречаются у курящих больных соответственно в 5, 6,5 и 3,5 раза чаще, по сравнению с некурящими. Доказано, что у курящих пациентов статистически значимо в 3 раза чаще присутствуют сопутствующие заболевания, что может являться причиной более тяжелого течения туберкулеза легких и затрудняет лечение. Табакокурение у пациентов с туберкулезом легких сопровождается бронхообструктивными нарушениями легких. ЗАКЛЮЧЕНИЕ Таким образом, табакокурение является значимым фактором, ассоциированным с распространенными клиническими формами туберкулеза легких и тяжелым течением заболевания.

8 December 2022 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
NCN. V. Chumovatov
N. V. Chumovatov
NCN. A. Chernyh
N. A. Chernyh
GSG. M. Saharova
G. M. Saharova
NAN. S. Antonov
N. S. Antonov
VRV. V. Romanov
V. V. Romanov
AEA. E. Ergeshov
A. E. Ergeshov
Introduction. At the end of 2020, the clinical cure rate in all registration groups of patients with pulmonary tuberculosis was 48.2 %. There is now ample evidence that additional risk factors influence the more severe course of pulmonary tuberculosis and reduce the effectiveness of standard anti-tuberculosis therapeutic programs. Diabetes mellitus and tobacco use are among the significant risk factors. Complementing standard TB therapeutic programs with nicotine addiction and diabetes mellitus treatment programs with the formation of an individual comprehensive patient treatment plan will increase the effectiveness of TB treatment. Thus, the goal of this work is to demonstrate the high effectiveness of an individualized approach to the treatment of a patient with pulmonary tuberculosis with a comorbid background.The aim of the work was to demonstrate the high effectiveness of an individualized approach to the treatment of a patient with pulmonary tuberculosis with a comorbid background.Materials and methods At the Central TB Research Institute the patient underwent a comprehensive examination, including mandatory, additional and facultative methods of investigation. Based on the findings, the patient underwent complex treatment: antituberculosis chemotherapy, correction of carbohydrate metabolism disorders using oral antidiabetic drugs, nicotine replacement therapy according to the selected scheme, taking into account the degree of nicotine addiction.Results and Discussion Against the background of complex treatment, by four months of therapy the following was achieved: knockdown of systemic inflammatory reactions, cessation of bacterial excretion, compensation of diabetes mellitus. X-ray examination revealed closure of a large decay cavity, resorption and consolidation of focal infiltrative changes. There was regression of infiltrative changes of trachea and bronchi. The patient completely stopped using tobacco due to nicotine replacement therapy.Conclusion This clinical example demonstrates the high effectiveness of an individualized approach to the treatment of tuberculosis, including the need for an individualized regimen of anti-tuberculosis therapy, adequate compensation for diabetes mellitus, and the implementation of relevant smoking cessation techniques among smokers with pulmonary tuberculosis.

12 December 2022 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
NCN. V. Chumovatov
N. V. Chumovatov
NAN. S. Antonov
N. S. Antonov
GSG. M. Sakharova
G. M. Sakharova
NCN. A. Chernyh
N. A. Chernyh
VRV. V. Romanov
V. V. Romanov
LRL. I. Rusakova
L. I. Rusakova
According to the WHO, tobacco use is currently the leading cause (16%) of all adult deaths. Studies conducted in many countries and in the Russian Federation have revealed the association between smoking and pulmonary tuberculosis (PT). Due to the negative impact of tobacco smoking on the course of tuberculosis and the effectiveness of treatment, there is a need to develop approaches to smoking cessation in patients with PT. Aim. To evaluate the effectiveness of the treatment of PT in smoking patients in combination with nicotine replacement therapy in an inpatient setting. Methods. The study included 27 patients with a confirmed diagnosis of PT. The inclusion criteria for the study were: age 18 years and older, patients who are currently active smokers, and a confirmed diagnosis of PT. The exclusion criteria were the presence of asthma and oncological diseases, unconfirmed diagnosis of PT, and earlier history of tobacco use. In the study group, an analysis of the smoking status was carried out. This status was based on the length of smoking period, number of cigarettes per day, and calculation of the smoking patient index. The degree of nicotine addiction, the presence of withdrawal symptoms, and the motivation of patients to quit smoking were assessed. The principle of nicotine dependence treatment was to prescribe nicotine-containing drugs in a dose depending on the degree of nicotine addiction. The duration of treatment was 12 weeks. Results. After 4 months of PT treatment, the cessation of bacterial excretion was detected 2 times more often, the closure of decay cavities in the lung tissue - 2.5 times more often, the relief of systemic inflammatory reactions - 2 times more often in patients who quit smoking than in patients who continue to smoke. Conclusion. This study showed that the treatment of PT in smokers was more effective in combination with nicotine replacement therapy for smoking cessation than when the patients continued to smoke.

19 March 2025 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
NCN.V. Chumovatov
N.V. Chumovatov
NCN.A. Chernyh
N.A. Chernyh
OKO.G. Komissarova
O.G. Komissarova
VRV.V. Romanov
V.V. Romanov
Pulmonary tuberculosis and malignant neoplasms (MNs) are important global healthcare issues. There has been a large number of studies on the relationship between pulmonary tuberculosis and MNs, but comprehensive approaches to diagnosis and treatment of these diseases need to be developed and implemented. Objective. To study the relationship between pulmonary tuberculosis and malignant neoplasms at the current stage of phthisiology. Materials and methods. Analysis of domestic and foreign databases for the period from 1976 to 2024 was performed. The following keywords were used for the search of literature: «tuberculosis», «cancer», «malignant neoplasms». Results. There is a large amount of publications in the world literature proving that the mechanisms of development of the tuberculous inflammation and the neoplastic process, in particular the formation of immune response, are similar, and this makes it difficult to timely detect and identify the pathological process. The cause-effect relationship of these diseases has been proven. As a result of this correlation, the tuberculous process increases the risk of MNs development by 3 times or more, and conversely, the development of the neoplastic process can lead to the risk of tuberculous infection accession or reactivation of «old» post-tuberculous changes. Tuberculosis and MNs have similar clinical symptoms, which complicates timely diagnosis and leads to establishment of misdiagnosis. Similarity of these two diseases is also found in X-ray examination. In this connection, the important direction at the current stage of phthisiology is to find comprehensive approaches to diagnosis, management and treatment of patients with tuberculosis and lung cancer. Conclusion. The results of the literature review showed a close relationship between the tuberculous process and malignant lung neoplasms. In immune disorders, a favorable environment for the development of both tuberculosis and neoplastic process is formed. Tuberculosis and malignant neoplasms have similar clinical and radiological symptoms, which complicates timely diagnosis and may lead to the establishment of misdiagnosis.

19 April 2024 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
NCN.V. Chumovatov
N.V. Chumovatov
OKO.G. Komissarova
O.G. Komissarova
NAN.S. Antonov
N.S. Antonov
GSG.M. Sakharova
G.M. Sakharova
Diabetes mellitus (DM) is among the leading non-contagious diseases with an annually growing prevalence. The frequency of non-contagious diseases associated with meaningful risk factors, including tobacco smoking, is also growing. At that, people with non-contagious diseases are more susceptible to infectious diseases, including lung tuberculosis (TB). TB is one of the leading contingent nosologies in incidence, which is in TOP10 most common causes of mortality. About 5—10% of people globally get TB during their lifecycles. However, the risk of contracting TB increases significantly against such risk factors as HIV infection, DM, tobacco smoking, malnutrition, and alcohol abuse. Lung TB diagnostics and treatment with co-morbidities is an acute issue. This is due to a growing DM incidence in the world and a wide spread of tobacco smoking. There are reports of a high prevalence of drug-resistant TB in these cohorts. Still, there is no current data on the clinical-epidemiological situation with the combination of these nosologies, as well as the approaches to managing and treating lung TB patients with DM prone to tobacco smoking.